articlePsychopharmacology BulletinAug 12, 2025Closed access

Paroxetine—The Antidepressant from Hell? Probably Not, But Caution Required

St. Elizabeth Youngstown Hospital

PubMed
Indexed incrossrefpubmed

Abstract

Paroxetine, also known by the trade names Aropax, Paxil, Pexeva, Seroxat, Sereupin and Brisdelle, was first marketed in the U.S. in 1992. Effective for major depression and various anxiety disorders, it quickly gained a sizable share of the antidepressant prescription market. By the late 1990s, paroxetine frequently was being associated with serious drug interactions and medication side effects. Most significantly, in a major Canadian epidemiological study examining the relationship between antidepressants and diseases, paroxetine was associated with a 620 percent increase in the rate of breast cancer in women who had taken it over a four-year period. Though re-analyses of this investigation discounted the…

Citation impact

94
total citations
FWCI
14.61
Percentile
100%
References
50
Citations per year

Authors

3

Topics & keywords

Keywords
  • Paroxetine
  • Antidepressant
  • Akathisia
  • Medicine
  • Adverse effect
  • Depression (economics)
  • Internal medicine
  • Tamoxifen
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.